Marzetti Reports Q3 Earnings Miss, Details $200M Term Loan for Bachan's Acquisition
summarizeSummary
Marzetti Co. reported a 1.0% decline in Q3 net sales and a 9.4% drop in diluted EPS, alongside detailing a new $200 million term loan to finance its $400 million acquisition of Bachan's, Inc.
check_boxKey Events
-
Q3 Financial Performance Misses
Net sales for the three months ended March 31, 2026, decreased 1.0% to $453.4 million, and diluted net income per common share fell 9.4% to $1.35 compared to the prior year.
-
Year-to-Date Growth Continues
For the nine months ended March 31, 2026, net sales increased 2.2% to $1,464.8 million, and diluted EPS grew 6.5% to $5.21, demonstrating overall positive performance despite the Q3 dip.
-
Bachan's Acquisition Financing Detailed
The company completed its $400 million acquisition of Bachan's, Inc. on May 1, 2026, partially funding it with a new $200 million term loan that closed on April 29, 2026.
-
Strong Cash Flow and Liquidity
Net cash provided by operating activities for the nine months increased to $228.7 million from $173.3 million, and the company remains in compliance with all debt covenants, expecting adequate liquidity for the next 12 months.
auto_awesomeAnalysis
Marzetti Co.'s Q3 2026 results show a decline in net sales and diluted EPS, falling short of expectations, which is particularly sensitive as the stock trades near its 52-week low. While year-to-date performance remains positive, the quarterly dip indicates potential headwinds. The company also provided details on the financing for its recently completed $400 million acquisition of Bachan's, Inc., securing a new $200 million term loan. This strategic acquisition, while aimed at growth, introduces additional debt. Investors should monitor the integration of Bachan's and the company's ability to manage debt while navigating a challenging retail environment and inflationary pressures.
At the time of this filing, MZTI was trading at $124.38 on NASDAQ in the Manufacturing sector, with a market capitalization of approximately $3.4B. The 52-week trading range was $122.63 to $190.96. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.